CompletedNot Applicable

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

United States158 participantsStarted 2008-02

Plain-language summary

This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how dactinomycin and vincristine affect the body and how patients will respond to treatment.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of cancer, including, but not limited to, any of the following: * Acute lymphoblastic leukemia * Ewing sarcoma * Rhabdomyosarcoma * Soft tissue sarcoma * Wilms tumor * Due to receive or receiving dactinomycin and/or vincristine as a component of cancer treatment on another clinical trial * Able to comply with study requirements * Other concurrent chemotherapeutic agents allowed

What they're measuring

Population PK parameters for dactinomycin and VCR

Timeframe: Not Provided

Demographic and/or physiological factors that are determinants of dactinomycin and VCR disposition

Timeframe: Not Provided

Trial details

NCT IDNCT00674193

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2016-06-30

View on ClinicalTrials.gov More Childhood Acute Lymphoblastic Leukemia trials